Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression (Q38412535)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 September 2015

Language	Label	Description	Also known as
English	Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression	scientific article published on 09 September 2015

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression (English)

1 reference

Europe PubMed Central

2 September 2017

tumor progression

1 reference

based on heuristic

inferred from title

Regan J. Anderson

object named as

Regan Anderson

4

0 references

author name string

Silke Neumann

1

1 reference

Europe PubMed Central

2 September 2017

Katie Young

2

1 reference

Europe PubMed Central

2 September 2017

Benji Compton

3

1 reference

Europe PubMed Central

2 September 2017

Gavin Painter

5

1 reference

Europe PubMed Central

2 September 2017

Sarah Hook

6

1 reference

Europe PubMed Central

2 September 2017

language of work or name

0 references

publication date

9 September 2015

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

33

1 reference

Europe PubMed Central

2 September 2017

43

1 reference

Europe PubMed Central

2 September 2017

5838-5844

1 reference

Europe PubMed Central

2 September 2017

Recent developments in cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Therapeutic cancer vaccines: are we there yet?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Vaccines against advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Immunological mechanisms of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

The contrasting roles of NKT cells in tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

CD1: antigen presentation and T cell function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Invariant NKT cells amplify the innate immune response to lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha -galactosylceramide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Harnessing invariant NKT cells in vaccination strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Particulate delivery systems for vaccines: what can we expect?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Immunostimulation of dendritic cells by cationic liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Diffusion of univalent ions across the lamellae of swollen phospholipids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Efficient synthesis of alpha-galactosyl ceramide analogues using glycosyl iodide donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Physical Characterization of Synthetic Phosphatidylinositol Dimannosides and Analogues in Binary Systems with Phosphatidylcholine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Novel murine dendritic cell lines: a powerful auxiliary tool for dendritic cell research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Modified thermoresponsive Poloxamer 407 and chitosan sol–gels as potential sustained-release vaccine delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Comparison of the Depot Effect and Immunogenicity of Liposomes Based on Dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged Liposome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

CD1 recognition by mouse NK1+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Identifiers

10.1016/J.VACCINE.2015.08.083

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38412535&oldid=2070853422"